Compare Johnson & Johnson (JNJ) vs Realty Income Corp (O) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Johnson & Johnson vs Realty Income Corp — how do they compare? Johnson & Johnson trades at $261.24 (market cap $618.09B), while Realty Income Corp trades at $54.18 (market cap $51.26B). The key difference: Johnson & Johnson is far larger — about 12.1× Realty Income Corp's market cap, and Realty Income Corp pays the higher dividend (6.01%). Which is the better fit depends on your goals — on Pluang, investors hold Johnson & Johnson for 129 Days and Realty Income Corp for 127 Days on average.
| JNJ | O | |
|---|---|---|
Market Cap | $618.09B | $51.26B |
Volume | 6,050,983 | 12,300,266 |
Sector | Health | Real Estate |
52-Week High | $278.43 | $67.56 |
52-Week Low | $186.00 | $53.35 |
Typical Hold Time | 129 Days | 127 Days |
Enterprise Value | $646.37B | $81.88B |
Dividend Yield | 2.09% | 6.01% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Johnson & Johnson (JNJ) trades at $259.62, up 0.45% with a bearish technical signal despite recent earnings beats. The stock shows strong fundamentals with 21.48% net margin and 25.74% ROE, though valuation ratios appear elevated with P/E at 29.75. Recent news highlights growth in the Innovative Medicine segment and positive analyst coverage with 52.5% buy ratings.
JNJ offers stable dividend income and pharmaceutical innovation upside, but faces patent cliff risks and increasing debt-to-asset ratio (24.06% in 2025). Analyst consensus target of $286.53 suggests 10% upside potential, though technical resistance at $260 may limit near-term gains.
Realty Income (O) trades at $54.09, down 1.39% amid a bearish technical signal and recent earnings misses. The stock faces pressure from rising Treasury yields, yet maintains a high gross margin of 92.56% and consistent dividend payments. Revenue growth is steady, with 2025 revenue at $5.75B, though net income margin has fluctuated. Analyst consensus is a Buy with a $64.80 price target, but technical indicators show resistance near $55.
The outlook for O hinges on its ability to navigate interest rate sensitivity while leveraging its robust property portfolio. Opportunities include a high dividend yield and strong operational cash flow, but risks involve debt levels nearing 40% of assets and competitive pressures in the REIT sector. Investor sentiment is cautious due to recent underperformance relative to the S&P 500.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →About Realty Income Corp
Realty Income owns roughly 11,400 properties, most of which are freestanding, single-tenant, triple-net-leased retail properties. Its properties are located in 49 states and Puerto Rico and are leased to 250 tenants from 47 industries. Recent acquisitions have added industrial, office, manufacturing, and distribution properties, which make up roughly 17% of revenue.
Read more on O →
